Gara Jalqabaatti › Kansarii Prostate › Tennessee › Nashville
Qorannoo klinikaalii Kansarii Prostate Nashville, TN keessatti
Qorannoo 43 Kansarii Prostate f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- GSK Investigational Site, Nashville
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Namoota walitti qabaa jiraSadarkaa 3
- Urology Associates, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
DESTINY-PANTUMOUR04
Namoota walitti qabaa jiraQorannoo ilaalaa
- Research Site, Nashville
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Namoota walitti qabaa jiraSadarkaa 3
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- Tennessee Oncology, PLLC - Nashville Saint Thomas West, Nashville
- fi 7 dabalataa
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Nashville
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute Oncology Partners, Nashville
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Namoota walitti qabaa jiraSadarkaa 3
- Urology Associates of Nashville, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Center, Nashville
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Oncology Nashville, Nashville
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Nashville
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Sarah Cannon Research Institute, Nashville
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
- United States Oncology Regulatory Affairs Corporate Office, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Namoota walitti qabaa jiraSadarkaa 2
- Henry-Joyce Cancer Clinic, Nashville
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Tennessee Oncology PLLC, Nashville
PSMA PET Combined With MRI for the Detection of PCa
Namoota walitti qabaa jiraSadarkaa 3Hojjettoota fayyaa simatamoo
- Urology Associates of Nashville, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Investigative Site #102, Nashville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Namoota walitti qabaa jiraSadarkaa 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Urology Associates PC, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Nashville
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
Qorannoo Kansarii Prostate magaalota biroo keessatti
- New York City, NYQorannoo 103
- Houston, TXQorannoo 76
- Los Angeles, CAQorannoo 61
- Boston, MAQorannoo 59
- St. Louis, MOQorannoo 46
- Chicago, ILQorannoo 45
- San Francisco, CAQorannoo 45
- Philadelphia, PAQorannoo 44
- Baltimore, MDQorannoo 43
- Seattle, WAQorannoo 42
- Washington, DCQorannoo 38
- Dallas, TXQorannoo 36
Qorannoo biroo Nashville keessatti
- Kansara Qara'a Non-Small CellQorannoo 97
- Saree OljooQorannoo 81
- Kansara MetastatikiiQorannoo 70
- Kansarii ColorectalQorannoo 69
- Saree (Gosoota Hunda)Qorannoo 65
- Kansarii OvariiQorannoo 49
- Dhibee QaraQorannoo 40
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 39
- Kansarii PancreasQorannoo 39
- Kansa EndometiriyaaliiQorannoo 38
- MelanomaQorannoo 33
- Myeloma Baay’eeQorannoo 32
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.